Business
Medical Marijuana, Inc. Major Investment AXIM Biotech Announces First-Ever Successful Achievement of Proprietary cGMP Extraction and Manufacturing Methods for Pure Cannabinoid Molecules
Medical Marijuana, Inc. Major Investment AXIM Biotech Announces First-Ever Successful Achievement of Proprietary cGMP Extraction and Manufacturing Methods for Pure Cannabinoid Molecules.
About this update from Axim Biotechnologies, Inc.
[{"type":"text","content":"\n\n\n\nMedical Marijuana, Inc. Major Investment AXIM Biotech Announces First-Ever Successful Achievement of Proprietary cGMP Extraction and Manufacturing Methods for Pure Cannabinoid Molecules\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nMedical Marijuana, Inc. Major Investment AXIM Biotech Announces First-Ever Successful Achievement of Proprietary cGMP Extraction and Manufacturing Methods for Pure Cannabinoid Molecules\nPR Newswire\nSAN DIEGO, Feb. 28, 2018\n\n\n\nSAN DIEGO, Feb. 28, 2018 /PRNewswire/ -- Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States, announced that its major investment company AXIM® Biotechnologies (OTC:AXIM) (\"AXIM\") has successfully executed their first-ever proprietary current good manufacturing practices (\"cGMP\") methodology in the extraction and microencapsulation of cannabinoid molecules for a variety of pharmaceutical delivery formats from cGMP-produced medicinal cannabis. \n\nThe breakthrough makes AXIM the only Company in the world with the ability to harness the proprietary procedure and provide Active Pharmaceutical Ingredients (\"APIs\") of such purity from naturally extracted cGMP sources.\n\n\"We're proud to see AXIM Biotech continue to be a pioneer in cannabinoid research,\" said Medical Marijuana, Inc. CEO Dr. Stuart Titus. \"We hope that this new extraction process will expand the pharmaceutical cannabinoid market and broaden the potential areas of application.\"\n\nAXIM's new methods are unprecedented in terms of the nature of the process - which utilizes cGMP standards employed from the initial growing of the cannabis plants through extraction and manufacturing - leading to the highest of quality standards for APIs being met.\n\nThe process, which was developed and tested in the Netherlands under strict regulatory guidelines, involves the growing of selected cannabis plants at a cGMP facility followed by extraction of the cannabinoid molecules from cannabis flowers in an innovative process that employs just two steps in order to achieve an average ...